AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03510455
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
Trial: NCT02018653
Drug: Calcium Alumina-Silicate (CASAD)
RxNorm normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram by mouth every 6 hours for up to 6 days.
Trial: NCT02036138
Drug: Advanced Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00220064
Drug: Irinotecan, 5-Fluorouracil, Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03217734
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Tablet
Trial: NCT03217734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT02447640
Drug: ADX48621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
Trial: NCT01063855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
Trial: NCT03549611
Drug: Multimodal Oral Drug Regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways
Trial: NCT03549611
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 975mg
Trial: NCT01037205
Drug: Respitose ML006 (DMV-Fonterra)
RxNorm normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL SPRAY [doTERRA sun]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate
Trial: NCT01342029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-1,000 mg po bid for 2 weeks
Trial: NCT01458054
Drug: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2336805 and Omeprazole
Trial: NCT01458054
Drug: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2336805 and Ritonavir
Trial: NCT00346996
Drug: insulin levemir / aspart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for subcutaneous injection
Trial: NCT00346996
Drug: human insulin /insulin isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for subcutaneous injection
Trial: NCT03106454
Drug: Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
Trial: NCT02767752
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02595320
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7).
Trial: NCT00854204
Drug: TMC114; TMC41629
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00345098
Drug: SR58611A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02973360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT00895843
Drug: Brufen retard
RxNorm normalized name: Brufen Retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 2 x 800mg tablets 2 hours prior to surgery
Trial: NCT00895843
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
Trial: NCT04446091
Drug: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs for colorectal mucinous adenocarcinoma
Trial: NCT02469155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01424813
Drug: Placebo MDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Trial: NCT02373579
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
Trial: NCT01722318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04149431
Drug: Derinat
RxNorm normalized name: Serine
DrugBank: Serine (DB00133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: desoxyribonucleate sodium
Trial: NCT01357642
Drug: Epinephrine inhalation aerosol
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
Trial: NCT01357642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for epinephrine inhalation aerosol, formulation without epinephrine
Trial: NCT01572740
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
Trial: NCT00478192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: premix bag
Trial: NCT02824354
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
Trial: NCT01689571
Drug: CHF6001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01689571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03537547
Drug: FDA-approved antidepressant or antipsychotic treatment
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant is treated with medications included in the GeneSight Psychotropic product.
Trial: NCT00077389
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00858689
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
Trial: NCT01038427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray administered once daily (4 actuations) for 14 days.
Trial: NCT02202785
Drug: MLN0264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN0264 IV infusion
Trial: NCT01549834
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose
Trial: NCT01549834
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose
Trial: NCT01549834
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04539483
Drug: HDIT101 (blinded therapy)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
Trial: NCT04539483
Drug: Placebo (blinded therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
Trial: NCT02686619
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
Trial: NCT01378520
Drug: inert powder
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral once
Trial: NCT02337205
Drug: KX2-391 Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
Trial: NCT04288349
Drug: epinephrine + ropivacaine +saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine + ropivacaine +saline
Trial: NCT04288349
Drug: epinephrine + saline
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epinephrine + saline
Trial: NCT04228926
Drug: ZKY001 eye drops 0.3g:0.006mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZKY001 eye drops of 0.002% continuously for up to 14±2 days after Corneal endothelial transplantation
Trial: NCT04228926
Drug: ZKY001 eye drops 0.3g:0.012mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZKY001 eye drops of 0.004% continuously for up to 14±2 days after Corneal endothelial transplantation
Trial: NCT00373451
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v. bolus of 70 units/kg/body weight of unfractionated heparin
Trial: NCT02336425
Drug: QGE031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 120 mg per 1 mL liquid in vial
Trial: NCT02336425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QGE031 0 mg per 1 mL liquid in vial
Trial: NCT03749135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00439192
Drug: ELB245
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00996606
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
Trial: NCT01067846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
Trial: NCT00753064
Drug: Antiscorpion venom serum(AScVS).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(\>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 \> 10-15 3 6 \>15- 21 4 8
Trial: NCT02910518
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT02910518
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: intravenous
Trial: NCT02810119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00577057
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01878396
Drug: Anti-B-RAF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00794625
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
Trial: NCT03623022
Drug: Clinical Center Reference Endotoxin (CCRE)
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
Trial: NCT03623022
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
Trial: NCT00259376
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT04048070
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
Trial: NCT02671500
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF/VEL (400/100 mg) FDC tablet administered orally once daily
Trial: NCT03568643
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children enrolled in the trial and randomized to azithromycin will receive a single directly observed dose of oral azithromycin at 20 mg/kg up to the maximum adult dose of 1 g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
Trial: NCT01459887
Drug: CHOP, CMAB304
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
Trial: NCT02626455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
Trial: NCT02626455
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Trial: NCT02626455
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Trial: NCT02240589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
Trial: NCT00558792
Drug: Isovue 370, 80 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
Trial: NCT00558792
Drug: Isovue 370, 90 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
Trial: NCT00023998
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00023998
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00023998
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT03006640
Drug: Subcutaneous nitroglycrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
Trial: NCT03006640
Drug: Subcutaneous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
Trial: NCT01499563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing inactive placebo for 28 days
Trial: NCT01825798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
Trial: NCT01395069
Drug: Nepafenac 0.1%
RxNorm normalized name: NEPAFENAC 0.1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop QID for 1 month
Trial: NCT00873262
Drug: Skin test panel and solvent
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml
Trial: NCT01606371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01606371
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02473965
Drug: IGIV-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks
Trial: NCT02473965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01240551
Drug: F-18 NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
Trial: NCT00078377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets once daily
Trial: NCT03554408
Drug: 3BNC117-LS
RxNorm normalized name: Emcor LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 3BNC117-LS
Trial: NCT03554408
Drug: 3BNC117-LS
RxNorm normalized name: Emcor LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3BNC117-LS
Trial: NCT00132678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo intramuscular (IM) injection every 2 weeks
Trial: NCT01395043
Drug: Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
Trial: NCT01727492
Drug: Antioxidantia
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00883103
Drug: Plain aqueous gel
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.